You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePlatelet Activating Factor
Accession NumberDB02261  (EXPT02559)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS number74389-68-7
WeightAverage: 523.6832
Monoisotopic: 523.363789599
Chemical FormulaC26H54NO7P
InChI KeyHVAUUPRFYPCOCA-AREMUKBSSA-N
InChI
InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3/t26-/m1/s1
IUPAC Name
(2-{[(2R)-2-(acetyloxy)-3-(hexadecyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
SMILES
CCCCCCCCCCCCCCCCOC[[email protected]](CO[P@@]([O-])(=O)OCC[N+](C)(C)C)OC(C)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Ganglioside GM2 activatorProteinunknownNot AvailableHumanP17900 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Platelet Activating Factor.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Platelet Activating Factor.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Platelet Activating Factor.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Platelet Activating Factor.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Platelet Activating Factor.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Platelet Activating Factor.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Platelet Activating Factor.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Platelet Activating Factor.Approved
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Platelet Activating Factor.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Platelet Activating Factor.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Platelet Activating Factor.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Platelet Activating Factor.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Platelet Activating Factor.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Platelet Activating Factor.Approved
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Platelet Activating Factor.Approved
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Platelet Activating Factor.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Platelet Activating Factor.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Platelet Activating Factor.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Platelet Activating Factor.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Platelet Activating Factor.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Platelet Activating Factor.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Platelet Activating Factor.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Platelet Activating Factor.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Platelet Activating Factor.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Platelet Activating Factor.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Platelet Activating Factor.Approved
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Platelet Activating Factor.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Platelet Activating Factor.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Platelet Activating Factor.Approved
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Platelet Activating Factor.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Platelet Activating Factor.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Platelet Activating Factor.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Platelet Activating Factor.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Platelet Activating Factor.Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Platelet Activating Factor.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Platelet Activating Factor.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Platelet Activating Factor.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Platelet Activating Factor.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Platelet Activating Factor.Illicit
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Platelet Activating Factor.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Platelet Activating Factor.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Platelet Activating Factor.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Platelet Activating Factor.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Platelet Activating Factor.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Platelet Activating Factor.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Platelet Activating Factor.Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Platelet Activating Factor.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Platelet Activating Factor.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Platelet Activating Factor.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Platelet Activating Factor.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Platelet Activating Factor.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Platelet Activating Factor.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Platelet Activating Factor.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Platelet Activating Factor.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Platelet Activating Factor.Approved
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Platelet Activating Factor.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Platelet Activating Factor.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Platelet Activating Factor.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Platelet Activating Factor.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Platelet Activating Factor.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Platelet Activating Factor.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Platelet Activating Factor.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Platelet Activating Factor.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Platelet Activating Factor.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Platelet Activating Factor.Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Platelet Activating Factor.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Platelet Activating Factor.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Platelet Activating Factor.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Platelet Activating Factor.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Platelet Activating Factor.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Platelet Activating Factor.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Platelet Activating Factor.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Platelet Activating Factor.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Platelet Activating Factor.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Platelet Activating Factor.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Platelet Activating Factor.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Platelet Activating Factor.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Platelet Activating Factor.Approved
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Platelet Activating Factor.Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Platelet Activating Factor.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Platelet Activating Factor.Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Platelet Activating Factor.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Platelet Activating Factor.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Platelet Activating Factor.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Platelet Activating Factor.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Platelet Activating Factor.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Platelet Activating Factor.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Platelet Activating Factor.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Platelet Activating Factor.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Platelet Activating Factor.Approved
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Platelet Activating Factor.Approved
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Platelet Activating Factor.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Platelet Activating Factor.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Platelet Activating Factor.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Platelet Activating Factor.Approved
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Platelet Activating Factor.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Platelet Activating Factor.Approved
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Platelet Activating Factor.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Platelet Activating Factor.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Platelet Activating Factor.Experimental
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Platelet Activating Factor.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Platelet Activating Factor.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Platelet Activating Factor.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Platelet Activating Factor.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Platelet Activating Factor.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Platelet Activating Factor.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Platelet Activating Factor.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Platelet Activating Factor.Approved
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Platelet Activating Factor.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Platelet Activating Factor.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Platelet Activating Factor.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Platelet Activating Factor.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Platelet Activating Factor.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Platelet Activating Factor.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Platelet Activating Factor.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Platelet Activating Factor.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Platelet Activating Factor.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Platelet Activating Factor.Approved
Food InteractionsNot Available
References
Synthesis Reference

Aiya Sato, Michihiro Sugano, Kouhei Furuya, Takeshi Oshima, Harumitsu Kuwano, Tadashi Hata, Hideyuki Haruyama, "Platelet activating factor antagonists, named “the phomactins”, their preparation and use." U.S. Patent US5308867, issued October, 1980.

US5308867
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9853
Blood Brain Barrier+0.8739
Caco-2 permeable-0.5288
P-glycoprotein substrateSubstrate0.5468
P-glycoprotein inhibitor INon-inhibitor0.708
P-glycoprotein inhibitor IINon-inhibitor0.8673
Renal organic cation transporterNon-inhibitor0.837
CYP450 2C9 substrateNon-substrate0.8951
CYP450 2D6 substrateNon-substrate0.8167
CYP450 3A4 substrateSubstrate0.5503
CYP450 1A2 substrateNon-inhibitor0.8835
CYP450 2C9 inhibitorNon-inhibitor0.895
CYP450 2D6 inhibitorNon-inhibitor0.9047
CYP450 2C19 inhibitorNon-inhibitor0.8362
CYP450 3A4 inhibitorNon-inhibitor0.7665
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9636
Ames testNon AMES toxic0.6905
CarcinogenicityCarcinogens 0.6219
BiodegradationReady biodegradable0.9563
Rat acute toxicity2.8285 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6381
hERG inhibition (predictor II)Non-inhibitor0.6618
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000225 mg/mLALOGPS
logP2.71ALOGPS
logP2.01ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)1.86ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area94.12 Å2ChemAxon
Rotatable Bond Count26ChemAxon
Refractivity151.67 m3·mol-1ChemAxon
Polarizability63.09 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1-alkyl,2-acylglycero-3-phosphocholines. These are glycerophosphocholines that carry exactly one acyl chain attached to the glycerol moiety through an ester linkage at the O2-position, and one alkyl chain attached through an ether linkage at the O1-position.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassGlycerophospholipids
Sub ClassGlycerophosphocholines
Direct Parent1-alkyl,2-acylglycero-3-phosphocholines
Alternative Parents
Substituents
  • 1-alkyl,2-acylglycero-3-phosphocholine
  • Phosphocholine
  • Dialkyl phosphate
  • Glycerol ether
  • Choline
  • Alkyl phosphate
  • Phosphoric acid ester
  • Organic phosphoric acid derivative
  • Organic phosphate
  • Acetate salt
  • Quaternary ammonium salt
  • Carboxylic acid ester
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase activator activity
Specific Function:
The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents...
Gene Name:
GM2A
Uniprot ID:
P17900
Molecular Weight:
20838.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23